ERBB2 and breast cancer: In a small, single site cohort of post-menopausal patients with metastatic ERBB2 mutant/non-amplified BC receiving neratinib and fulvestrant from the studies described above, peripheral blood (PB) samples were collected as liquid biopsies during treatment and analyzed to characterize CTCs and cfDNA.